Pyxis Oncology (PYXS) Total Current Liabilities (2020 - 2026)

Pyxis Oncology (PYXS) has reported Total Current Liabilities for 7 consecutive years, with $27.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Current Liabilities rose 55.41% year-over-year to $27.5 million in Q2 2026; TTM through Jun 2026 was $27.5 million, a 55.41% increase from a year earlier, with the FY2025 full-year figure at $21.1 million, up 19.52% from the prior year.
• Total Current Liabilities was $27.5 million for Q2 2026 at Pyxis Oncology, up from $21.1 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $31.6 million in Q4 2022 and troughed at $9.2 million in Q2 2023.
• A 5-year average of $19.3 million and a median of $19.1 million in 2022 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities plunged 39.54% in 2023 and surged 83.17% in 2024, its largest moves.
• Over 5 years, Total Current Liabilities stood at $31.6 million in 2022, then retreated by 18.57% to $25.8 million in 2023, then tumbled by 31.36% to $17.7 million in 2024, then climbed by 19.52% to $21.1 million in 2025, then jumped by 30.02% to $27.5 million in 2026.
• The last three Total Current Liabilities figures came in at $27.5 million (Q2 2026), $21.1 million (Q4 2025), and $19.4 million (Q3 2025), per Business Quant data.